743-P: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes

743-P: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes

Introduction & Objective: In the SURPASS-6 trial, tirzepatide (TZP) added to basal insulin glargine U100 significantly improved HbA1c and body weight in participants with inadequately controlled type 2 diabetes (T2D). Overall, basal insulin dose decreased over time, and up to 19% of TZP-treated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1
Hauptverfasser: WYSHAM, CAROL H., ROSENSTOCK, JULIO, TOFE, SANTIAGO, THIEU, VIVIAN, KILJANSKI, JACEK I., LEE, CLARE, WANG, HUI, PATEL, HIREN
Format: Artikel
Sprache:eng
Schlagworte:
Antidiabetics
Body weight
Diabetes
Diabetes mellitus (non-insulin dependent)
Insulin
Multivariate analysis
Regression analysis
Triglycerides
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction & Objective: In the SURPASS-6 trial, tirzepatide (TZP) added to basal insulin glargine U100 significantly improved HbA1c and body weight in participants with inadequately controlled type 2 diabetes (T2D). Overall, basal insulin dose decreased over time, and up to 19% of TZP-treated participants discontinued basal insulin by Week 52. We aimed to identify clinical parameters associated with insulin regression (use
ISSN:0012-1797
1939-327X
DOI:10.2337/db24-743-P